4.6.4. disease management. evaluating results trials involving treatment strategies nocturia, vital examine clinical significance statistical significance achieved small reductions nocturia episodes. 4.6.4.1. conservative management individual components self-management critically evaluated recommendations traditionally derived consensus methodology. interventions listed may help nocturia but, majority, quantification effect possible: reduction fluid intake specific times;avoidance/moderation intake caffeine alcohol;distraction techniques;bladder retraining;pelvic floor muscle training;reviewing medication;treatment constipation. available data conservative treatment nocturia show significant heterogeneity. sr , three studies [603-605] favourable conservative treatment pfmt, another failing confirm benefit . highest level evidence comes study 131 patients (a secondary analysis prospective rct urgency-predominant ui primary inclusion criterion). study found training pfm contraction, included four sessions biofeedback-assisted pfmt, reduced nocturia median 0.50 episodes per night significantly effective anticholinergic drug treatment placebo . certainty evidence associated treatment moderate. smaller rct 50 women urinary complaints, randomised 1:1 bt pfmt compared control group receiving treatment, showed significant decrease patients’ complaints nocturia . another rct 24 women compared pfmt interferential therapy plus . although authors find significant differences groups, change nocturia episodes treatment statistically significant groups. study underpowered authors’ admission. level certainty evidence two trials low. large randomised, two-arm, parallel design, superiority trial (n = 647; women), compared effects unsupervised behavioural pfmt programmes delivered two-hour class format 20 minutes video format ui prevention. significant between-group differences nocturia observed 3 months 12 months, 24 months, women 2 hour class group less likely fewer nocturia episodes (or = 0.5; 95 % ci: 0.3−0.7; p = 0.005) compared 20 minutes video group, authors concluded evidence sufficient support one management strategy . multicentre, open-labelled, rct evaluated whether cognitive behavioural therapy (cbt) using self-assessment via checklist effective improving nocturia mixed population (30/78 women). mean rate achievement cbt group 64.4%. significant difference two groups night-time frequency based ipss q7 four weeks episodes nocturia frequency volume chart (fvc) significantly smaller cbt group (1.9 ± 0.9) control group (2.4 ± 1.3; p = 0.039) . secondary analysis prospective rct, 210 women urgency ui (uui) evaluated change baseline number episodes nocturia nocturnal incontinence groups allocated medical treatment (tolterodine er 4 mg) alone vs. medical treatment plus pfmt . significant difference groups found actual difference nocturia episodes either treatment arm small. level certainty evidence trial low. recent rct explored individual group pfmt specific secondary outcome number patients two nocturia episodes per night . authors reported similar reductions, > 30% patients > 2 episodes nocturia baseline longer experiencing level symptoms one year pfmt. one small, single-centre rct functional magnetic stimulation compared treatment 39 women reported significant decrease nocturia (together voiding frequency pad use) treatment group compared control group . patients obstructive sleep apnoea complain nocturia, continuous positive airway pressure shown effective sr meta-analysis five rcts involving sexes . treatment associated average numerical reduction nocturia > 2 episodes per night. 4.6.4.1.1. summary evidence recommendations conservative management nocturia summary evidenceleindividual group pfmt appears equally effective reduction nocturia episodes.1bmost studies evaluating pfmt nocturia women additional urinary symptoms shown positive results compared placebo anticholinergic drugs.1btreatment nocturia secondary obstructive sleep apnoea continuous positive airway pressure reduces nocturia episodes.1a recommendationsstrength ratingoffer women lower urinary tract symptoms (luts) lifestyle advice prior to, concurrent with, treatment.strongoffer pelvic floor muscle training nocturia (either individually group setting) women urinary incontinence storage luts.strongoffer women nocturia history suggestive obstructive sleep apnoea referral sleep clinic assessment suitability continuous positive airway pressure treatment.strong 4.6.4.2. pharmacological management 4.6.4.2.1. desmopressin desmopressin synthetic analogue hormone vasopressin often used management nocturia due nocturnal polyuria. sr , three trials specifically conducted women found additional data could extracted studies mixed populations. earliest evidence comes 1982 single-site crossover trial involving 25 women treated 20 g desmopressin placebo revealed significant decrease nocturnal urine output six weeks . recent multicentre, multinational double-blind rct involving 141 women used desmopressin 0.1, 0.2 0.4 mg orally bedtime dose-titration period . increased likelihood positive outcome non-responders excluded stage. three weeks, significant reductions nocturnal urinary frequency nocturnal diuresis reported. another multicentre double-blind rct, 58 women randomised five groups (twelve receiving placebo, twelve desmopressin 10 μg, eleven desmopressin 25 μg, eleven desmopressin 50 μg twelve desmopressin 100 μg) four weeks . dose–response relationship observed, women appeared sensitive men desmopressin. significant changes nocturnal urine volumes reported favour higher desmopressin doses. differences nocturnal polyuria index also tended favour desmopressin placebo higher desmopressin doses. level certainty evidence trials low. desmopressin safely combined anticholinergics significant benefit women oab nocturnal polyuria, shown multicentre rct 97 patients . post hoc analysis data comparing three-month once-daily combination (desmopressin 25 μg/tolterodine 4 mg, n = 49) monotherapy (tolterodine 4 mg/placebo, n = 57) revealed significant reduction nocturnal void volume time first nocturnal void favour combination therapy. level certainty evidence trial moderate. pooled data three rcts used examine adverse event profile desmopressin, specifically hyponatraemia . authors reported majority tolerate desmopressin treatment without clinically significant hyponatraemia, risk increased age lower baseline serum sodium concentration. advised desmopressin treatment elderly patients include careful monitoring serum sodium concentration avoided patients baseline serum sodium concentration normal range. 4.6.4.2.2. anticholinergics sr identified three rcts involving anticholinergics oxybutynin 2.5 mg/day tolterodine 4 mg/day . secondary analysis prospective rct involving 131 women nocturia followed eight weeks found women receiving 2.5 mg immediate-release oxybutynin daily (with possibility self-titration dose escalation 5 mg three times daily) fewer nocturia episodes women receiving placebo . women receiving oxybutynin plus behavioural therapy also exhibited significant decrease nocturia episodes compared placebo oxybutynin alone. multicentre rct 305 women followed eight weeks examined efficacy tolterodine tartrate 4 mg alone combination behavioural training . significant differences compared baseline observed mean nocturia episodes nocturnal incontinence episodes groups, difference reported two treatment groups. level certainty evidence trial moderate. rct including 97 women nocturnal polyuria oab syndrome, comparing three months daily combination (desmopressin 25 μg/tolterodine 4 mg, n = 49) monotherapy (tolterodine 4 mg/placebo, n = 57), significant reduction mean number nocturnal voids compared baseline reported groups . level certainty evidence trial moderate. large comparative study followed 407 women oab nocturia four weeks . patients given tolterodine monotherapy one group, tolterodine combined estazolam (a benzodiazepine) group. significant changes baseline groups main outcome number nocturia episodes reported. combination therapy showed significant benefit women oab nocturia compared monotherapy terms differences number nocturia episodes, urgency episodes 24 hours, uui episodes 24 hours, voided volume per micturition. level certainty evidence trial low. small multicentre rct compared oxybutynin patch vs. mirabegron nocturia-related qol women oab. treatments showed improvements n-qol score four weeks, mirabegron showed statistical differences eight weeks. additionally, mirabegron decreased nocturnal frequency water intake, prolonged hours uninterrupted sleep eight weeks administration statistical significance, whereas oxybutynin patch . 4.6.4.2.3. oestrogens sr , single rct investigating efficacy oestrogen nocturia identified . trial compared oestradiol-releasing vaginal ring oestriol vaginal pessary 251 women followed six months. difference treatment groups number women reporting nocturia, although reported significant change baseline treatment arms > 50% subjects responding arm. certainty evidence outcome low. 4.6.4.2.4. diuretic treatment randomised placebo-controlled study afternoon dose 40 mg furosemide (taken six hours bedtime) attempt establish complete diuresis bedtime given elderly men . 43 men completed study, night-time frequency furosemide group fell 0.5 episodes compared placebo, percentage night-time voided volume fell 18%. study carried female patients. 4.6.4.3. summary evidence recommendations pharmacological management nocturia summary evidenceledesmopressin treatment nocturia shows significant reductions nocturnal urine output, nocturnal urinary frequency, nocturnal polyuria index.1bmost nocturia patients tolerate desmopressin treatment without clinically significant hyponatraemia; however, risk increases increasing age decreasing baseline serum sodium concentration.1atreatment nocturia oab patients anticholinergic drugs shows reduction nocturia episodes.1bcombination pfmt anticholinergics appear confer additional benefit anticholinergics alone.1bcombination anticholinergic desmopressin treatment appears reduce nocturnal voided volume time first nocturnal void women nocturnal polyuria.1bvaginal oestrogen may beneficial treatment nocturia around 50% women.1bafternoon (timed) diuretic treatment furosemide reduces nocturia episodes nocturnal voided volume men similar studies conducted women.1bassessment clinical significance important evaluating trials involving treatment strategies nocturia, statistical significance achieved small reductions nocturia episodes.3 recommendationsstrength ratingoffer desmopressin treatment nocturia secondary nocturnal polyuria women, following appropriate counselling regarding potential benefits associated risks (including hyponatraemia).strongcarefully monitor serum sodium concentration elderly patients treated desmopressin. avoid prescribing desmopressin patients baseline serum sodium concentration normal range.strongoffer anticholinergic treatment nocturia women urge urinary incontinence luts, following appropriate counselling regarding potential benefits associated risks.stronginform women nocturia combination behavioural therapy anticholinergic drugs unlikely provide increased efficacy compared either modality alone.weakoffer combination anticholinergics desmopressin women overactive bladder nocturia secondary nocturnal polyuria, following appropriate counselling regarding potential benefits associated risks.weakoffer vaginal oestrogen treatment women nocturia, following appropriate counselling regarding potential benefits associated risks.weakoffer timed diuretic treatment women nocturia secondary polyuria, following appropriate counselling regarding potential benefits associated risks.weak 4.6.4.4. surgical management surgical treatment generally reserved underlying correctable lut disorders. effect surgical treatments symptoms nocturia found relevant condition-specific sections guideline.